

1 Federal Regulations (or any successor regula-
2 tion).

3 “(c) AUTHORIZATION OF APPROPRIATIONS.—There
4 are authorized to be appropriated to carry out this section
5 \$3,000,000 for each of fiscal years 2016 through 2020.”.

6 **SEC. 2063. STREAMLINED DATA REVIEW PROGRAM.**

7 (a) IN GENERAL.—Chapter V of the Federal Food,
8 Drug, and Cosmetic Act, as amended by section 2062, is
9 further amended by inserting after section 505G of such
10 Act the following:

11 **“SEC. 505H. STREAMLINED DATA REVIEW PROGRAM.**

12 “(a) IN GENERAL.—The Secretary shall establish a
13 streamlined data review program under which a holder of
14 an approved application submitted under section
15 505(b)(1) or under section 351(a) of the Public Health
16 Service Act may, to support the approval or licensure (as
17 applicable) of the use of the drug that is the subject of
18 such approved application for a new qualified indication,
19 submit qualified data summaries.

20 “(b) ELIGIBILITY.—In carrying out the streamlined
21 data review program under subsection (a), the Secretary
22 may authorize the holder of the approved application to
23 include one or more qualified data summaries described
24 in subsection (a) in a supplemental application if—

1 “(1) the drug has been approved under section
2 505(c) of this Act or licensed under section 351(a)
3 of the Public Health Service Act for one or more in-
4 dications, and such approval or licensure remains in
5 effect;

6 “(2) the supplemental application is for ap-
7 proval or licensure (as applicable) under such section
8 505(c) or 351(a) of the use of the drug for a new
9 qualified indication under such section 505(c) or
10 351(a);

11 “(3) there is an existing database acceptable to
12 the Secretary regarding the safety of the drug devel-
13 oped for one or more indications of the drug ap-
14 proved under such section 505(c) or licensed under
15 such section 351(a);

16 “(4) the supplemental application incorporates
17 or supplements the data submitted in the application
18 for approval or licensure referred to in paragraph
19 (1); and

20 “(5) the full data sets used to develop the quali-
21 fied data summaries are submitted, unless the Sec-
22 retary determines that the full data sets are not re-
23 quired.

24 “(c) PUBLIC AVAILABILITY OF INFORMATION ON
25 PROGRAM.—The Secretary shall post on the public website

1 of the Food and Drug Administration and update annu-
2 ally—

3 “(1) the number of applications reviewed under
4 the streamlined data review program;

5 “(2) the average time for completion of review
6 under the streamlined data review program versus
7 other review of applications for new indications; and

8 “(3) the number of applications reviewed under
9 the streamlined data review program for which the
10 Food and Drug Administration made use of full
11 data sets in addition to the qualified data summary.

12 “(d) DEFINITIONS.—In this section:

13 “(1) The term ‘qualified indication’ means—

14 “(A) an indication for the treatment of
15 cancer, as determined appropriate by the Sec-
16 retary; or

17 “(B) such other types of indications as the
18 Secretary determines to be subject to the
19 streamlined data review program under this
20 section.

21 “(2) The term ‘qualified data summary’ means
22 a summary of clinical data intended to demonstrate
23 safety and effectiveness with respect to a qualified
24 indication for use of a drug.”.

1 (b) SENSE OF CONGRESS.—It is the sense of Con-
2 gress that the streamlined data review program under sec-
3 tion 505H of the Federal Food, Drug, and Cosmetic Act,
4 as added by subsection (a), should enable the Food and
5 Drug Administration to make approval decisions for cer-
6 tain supplemental applications based on qualified data
7 summaries (as defined in such section 505H).

8 (c) GUIDANCE; REGULATIONS.—The Commissioner
9 of Food and Drugs—

10 (1) shall—

11 (A) issue final guidance for implementation
12 of the streamlined data review program estab-
13 lished under section 505H of the Federal Food,
14 Drug, and Cosmetic Act, as added by sub-
15 section (a), not later than 24 months after the
16 date of enactment of this Act; and

17 (B) include in such guidance the process
18 for expanding the types of indications to be
19 subject to the streamlined data review program,
20 as authorized by section 505H(c)(1)(B) of such
21 Act; and

22 (2) in addition to issuing guidance under para-
23 graph (1), may issue such regulations as may be
24 necessary for implementation of the program.